Benjamin L. Palleiko - Nov 17, 2025 Form 4 Insider Report for KalVista Pharmaceuticals, Inc. (KALV)

Role: CHIEF EXECUTIVE OFFICER, Director
Signature: /s/ Benjamin L. Palleiko
Stock symbol: KALV
Transactions as of: Nov 17, 2025
Transactions value $: -$64,665
Form type: 4
Date filed: 11/19/2025, 04:13 PM
Previous filing: Nov 13, 2025
Next filing: Nov 26, 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Palleiko Benjamin L	CHIEF EXECUTIVE OFFICER, Director	C/O KALVISTA PHARMACEUTICALS, INC., 200 CROSSING BOULEVARD, FRAMINGHAM	/s/ Benjamin L. Palleiko	2025-11-19	0001366244

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	KALV	Common Stock	Options Exercise		+9.36K	+2.35%		408K	Nov 17, 2025	Direct	F1
transaction	KALV	Common Stock	Sale	-$64.7K	-4.47K	-1.09%	$14.48	404K	Nov 18, 2025	Direct	F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	KALV	Restricted Stock Unit	Options Exercise	$0	-2.42K	-33.33%	$0.00	4.84K	Nov 17, 2025	Common Stock	2.42K		Direct	F1, F4
transaction	KALV	Restricted Stock Unit	Options Exercise	$0	-6.95K	-100%	$0.00	0	Nov 17, 2025	Common Stock	6.95K		Direct	F1, F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
F2	The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
F3	The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.16 to $14.4835 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4	1/16th of the total number of shares subject to the RSU shall vest on each quarterly anniversary of the Vesting Commencement Date, subject to continued service through each vesting date.
F5	1/12th of the total number of shares subject to the RSU shall vest on each quarterly anniversary of the Vesting Commencement Date, subject to continued service through each vesting date.